AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05735717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: As seizures have occurred following high dose busulfan, all patients will be treated with Keppra beginning day -6 and continuing until day -1 per institutional guidelines.
Study NCT04274426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will administered by intravenous route
Study NCT06028711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education program
Description: Patients in a study group will participate in daily education program using an original brochure containing information on the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise, and risk factors for exacerbation of COPD.
Study NCT04274426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will administered by intravenous route
Study NCT04274426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: PLD will be administered by intravenous route
Study NCT04274426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered by intravenous route
Study NCT04274426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered by intravenous route
Study NCT04274426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Mirvetuximab Soravtansine will be administered by intravenous route
Study NCT04999592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care without prophylaxis
Description: Administer antibiotics in response to infection
Study NCT04999592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Description: Ceftriaxone 2 gm IV q12h for 3 days
Study NCT06649877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6194
Description: single injected dose
Study NCT06389240 — intervention group
Intervention type: OTHER
Intervention: 6 weeks post-operatively early weight bearing
Description: Early mobilization 6 weeks post-operatively. Gait analyses is carried out on when full mobilization is allowed. Gait analysis is performed while using force-measuring insoles (loadsol, Novel).
Study NCT06389240 — intervention group
Intervention type: OTHER
Intervention: 10 weeks post-operatively weight bearing (standard of care)
Description: Standard of care mobilization at 10 weeks post-operatively. Gait analyses is carried out on when full mobilization is allowed. Gait analysis is performed while using force-measuring insoles (loadsol, Novel).
Study NCT05416125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine Dimesylate
Description: Vyvanse treatment
Study NCT05416125 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle therapy
Description: Lifestyle treatment
Study NCT06023953 — intervention group
Intervention type: DEVICE
Intervention: Nerivio device
Description: REN treatment with Nerivio device
Study NCT04983095 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: 30 Gy in 3 fractions alternatively 40 Gy in 5 fractions delivered with stereotactic radiotherapy-principles
Study NCT04983095 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy
Description: Medical castration and next-generation Hormonal Agent along with radiotherapy to the prostate in de novo oligometastatic prostate cancer
Study NCT04983095 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: androgen deprivation therapy
Description: Medical castration and next-generation Hormonal Agent along with radiotherapy to the prostate in de novo oligometastatic prostate cancer
Study NCT04983095 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: RT to the prostate for de novo patients
Study NCT04983095 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: RT to the prostate for de novo patients
Study NCT05494151 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Investigation of the metabolic substrate
Description: A blood sample will be received from each patient to assess novel metabolomic biomarkers' levels at the time of acute myocardial infraction
Study NCT06146517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clevr Sleeptime
Description: Participants will trial Clevr Blends Sleeptime during weeks 1-4.
Study NCT06146517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clevr Matcha
Description: Participants will trial Clevr Matcha during weeks 5-8.
Study NCT06146517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clevr Chai
Description: Participants will trial Clevr Chai during weeks 9-12.
Study NCT06652269 — intervention group
Intervention type: OTHER
Intervention: Psychopharmacology intervention
Description: Psychotherapy with horses
Study NCT06652191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct catheterization with non-dilation
Description: Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, place the catheter into the vessel directly along the guide wire without using an dilator to expand the skin
Study NCT06652191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheterization after expanding the skin with a dilator
Description: Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, after the skin is expanded with a dilator, the catheter is inserted into the vessel along the guide wire
Study NCT06651996 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: one session of face-to-face telerehabilitation tutorial (OST)
Description: The first group participated in a face-to-face tele-rehabilitation session in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
Study NCT06651996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three session of face-to-face telerehabilitation tutorials (TST)
Description: The second group participated in three face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
Study NCT06651996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Six session of face-to-face telerehabilitation tutorials (SST)
Description: The third group participated in six face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
Study NCT06651645 — intervention group
Intervention type: OTHER
Intervention: COVID-19 Surge
Description: Impact of COVID-19 pandemic on hospital care delivery
Study NCT06028711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of two hours daily. The program will be applied individually to each patient and include active and assisted exercises, effective cough exercises, pursed-lips breathing, positive expiratory pressure exercises, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
Study NCT06028711 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary rehabilitation
Description: The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of two hours daily. The program will be applied individually to each patient and include active and assisted exercises, effective cough exercises, pursed-lips breathing, positive expiratory pressure exercises, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
Study NCT05676034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX0035
Description: AMX0035
Study NCT03935451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 milligram
Description: 2.5 milligram daily dosing of Apixaban beginning on the first day of hospital discharge for a total of 30 days
Study NCT05418842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: In addition to usual care, the prehabilitation group will exercise 3 times a week, starting immediately after diagnosis and throughout the pre-treatment period. Each exercise session will encompass 5-min warm-up and 45-min conditioning exercises. Aerobic training will be performed using low-volume high intensity interval training (HIIT). The HIIT duration is 16-20 minutes and it will be performed with 8-10 intervals of high intensity (1 minute) and 8-10 intervals of low intensity (1 minute). High intensity intervals will be set to an external load that represents 85-90% of estimated VO2Peak. In addition, patients will do resistance training at moderate intensity. Patients will complete 2 sets of 12 repetitions of 5 upper and lower body exercises.
Study NCT06327139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 5 point closed face immobilisation mask.
Description: The conventional closed face mask is a standard of care immobilization device for head and neck cancer patients which covers and immobilizes the entire anterior portion of the patients head, neck and shoulders using a semi rigid thermoplastic material.
Study NCT06327139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5 point open face immobilization mask
Description: The 5 point open face mask is a type of immobilization device for head and neck cancer patients which does not cover the patients face or chest. The device uses a semi rigid thermoplastic material and covers from the superior aspect of the patients head to the level of their clavicle.
Study NCT06327139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 point open face immobilization mask
Description: The 3 point open face mask is a type of immobilization device for head and neck cancer patients which does not cover the patients face. The device uses a semi rigid thermoplastic material and covers from the superior aspect of the patients head to the below the patients chin. The three point mask does not cover the patients shoulders and does not extend inferiorly to the level of the clavicle.
Study NCT05712083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T cells
Description: Each subject receive BCMA CAR T-cells by intravenous infusion
Study NCT06349044 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）
Description: RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.
Study NCT06349044 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）
Description: RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.
Study NCT06349044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-PD-1 monoclonal antibody
Description: Sintilimab 200mg d1 iv q3w
Study NCT06349044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Sintilimab 200mg d1 iv q3w
Study NCT06349044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin and Capecitabine
Description: Oxaliplatin130mg/m2 d1 iv；Capecitabine1000mg/m2 d1-d14
Study NCT06349044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and Capecitabine
Description: Oxaliplatin130mg/m2 d1 iv；Capecitabine1000mg/m2 d1-d14
Study NCT06349044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-VEGF 15mg/kg
Description: Bevacizumab 15mg/kg d1 iv q3w
Study NCT06349044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF 15mg/kg
Description: Bevacizumab 15mg/kg d1 iv q3w
Study NCT06349044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-VEGF 7.5mg/kg
Description: Bevacizumab 7.5mg/kg d1 iv q3w
Study NCT06349044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF 7.5mg/kg
Description: Bevacizumab 7.5mg/kg d1 iv q3w
Study NCT06349044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine and Cisplatin
Description: Gemcitabine1000mg/m2 d1 d8 iv；Cisplatin 25mg/m2 d1 d8 iv q3w
Study NCT06349044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin
Description: Gemcitabine1000mg/m2 d1 d8 iv；Cisplatin 25mg/m2 d1 d8 iv q3w
Study NCT03935451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo oral tablet that resembles the experimental drug. To be taken with the same frequency and duration
Study NCT05480488 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Subjects will receive a single oral dose of 2 mg midazolam (Treatment A, B, and C).
Study NCT05480488 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: Subjects will receive a single oral dose of 25 mg warfarin (Treatment A and B).
Study NCT05480488 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Daridorexant
Description: Subjects will receive an o.d. oral dose of 50 mg daridorexant from Day 1 to Day 7 of Treatment B and a single oral dose of 50 mg daridorexant on Day 1 of Treatment C.
Study NCT05608785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI315
Description: IBI315 is a recombinant fully humanized anti-programmed death receptor 1 (PD-1) and humanized anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody injection.
Study NCT05608785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
Study NCT05451407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection
Description: Humanized IgG4 mab targeting TIM-3
Study NCT05451407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab injection
Description: Monoclonal antibody against Programmed death factor receptor 1
Study NCT05608785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
Study NCT05608785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 is a high-affinity humanized monoclonal antibody targeting Claudin 18.2 with enhanced antibody-dependent cytotoxic (ADCC) and complement-dependent cytotoxic (CDC) activity, showing potent antitumor activity in xenograft assays.
Study NCT05608785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study NCT05608785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anrotinib
Description: Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.
Study NCT05559619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Description: 1000 mg of natural calcium carbonate once daily for 12 weeks
Study NCT05559619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 1000 IU vitamin D3 once daily for 12 weeks
Study NCT06649630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0442-0344 A
Description: SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.
Study NCT05559619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser acupuncture therapy
Description: The patient was in crock lying for stimulation of acupoints in abdomen and lower limbs then asked to be in side lying for stimulation of acupoints in the back. After disinfection of the skin and careful localization of the acupoints, low level laser therapy (LLLT) (model: Lis 1050, SN: EM 13481014, manufactured by EME srl, Italy) was applied bilaterally on Dazhu (BL 11), Ganshu(BL 18), Pishu (BL20), Shenshu (BL23), Zusanli (ST 36), Sanyinjiao (Sp6), Jingmen(GB25), Yanglingquan (GB34) andXuanzhong (GB39) acupoints, while it was applied in the midline on Guanyuan (CV4) andMingmen (GV4) acupoints. Each acupoint was irradiated for 60 sec, with total duration of 20 min, wave length of 905 nm, average radiant power output of 12 mW, energy density of 2 J/cm2, pulse radiation of 200 ms and pulse frequency of 5000 Hz
Study NCT04646616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community popular opinion leader (POL) based intervention
Description: A community popular opinion leader (POL) based intervention to promote measures to reduce COVID-19 risk, transmission, access to testing and treatment, reduction of the impact of COVID-19, and addressing the Substance Abuse, Violence, HIV/AIDS, and MEntal health (SAVAME) syndemic in the community. POLs will interact within their networks counseling regarding COVID-19 and SAVAME factors. The POLs will refer individuals to appropriate community services. POLs will record basic sociodemographic characteristics of all community contacts, the issue addressed, and their response to it. The first 300 community contacts will be invited to complete a baseline and 3-month follow up surveys (via internet or phone). The content of the surveys includes: 1) COVID-19 related questions (knowledge, impact, symptoms, risk factors, access to testing and care, acceptability contact tracing, vaccine) 2) Biological risk factors, 3) Social determinants of health, 4) SAVAME outcomes and access to services.
Study NCT05210920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nail polish application
Description: After application of nail polish as described, participants will have bacterial swabs collected from the under the fingernail and from the nail bed of the three assigned fingers on their dominant hand, both before and after scrubbing with a chlorhexidine surgical scrubbing brush.
Study NCT06142955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGSTIM Rapid2 TMS system
Description: The device will administer TMS pulses in bursts at fixed intervals for a total of 600 pulses over 190 seconds after first assessing the participants motor threshold (MT). During the sham stimulation condition, the TMS coil will be tilted 90° tangential to the scalp during the administration so that the orientation is not biologically active and will not elicit a muscle contraction. This sham condition will look and sound just like real TMS.
Study NCT05375513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PMI@Home
Description: Personalized multidomain interventional program by combining tailored lifestyle interventions that targets 5 domains: physical activity, cognition, diet, sleep, and vascular risk factors. These interventions are tailored based on participants' baseline profile and progress in intensity following the principles of personalized medicine. All aspects of the PMI@home will be delivered remotely, at participants' homes, using a digital platform with scheduled bi-weekly 1-to1 coaching sessions. Delivery of interventions and assessments are centralized with 5 trained staff at the sponsor site (London) to assure logistics, standardization, and quality control.
Study NCT05375513 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brain Health Pro
Description: Online Modules:~* Motivation, Self-Efficacy, Positive Health, Environment and Genetic risk~* Physical Activity~* Cognitively Stimulating Activities~* Diet~* Sleep~* Social and Psychological Health~* Vascular health~* Vision and Hearing~* Lifestyle Risk Impact Surveys~* Goal Setting
Study NCT05100875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills and Emotion Regulation Training SSERT
Description: The SSERT intervention will broadly consist of the following 10 modules: (1) Introducing the Participant to Treatment; (2-3) Emotional Awareness and Recognition; (4-5) Emotion Regulation and Understanding Emotions in the Context of Psychotic Experiences; (6) Living an Emotionally Engaged Life; (7) Understanding Relationship Patterns in the Context of Psychosis; (8) Changing Undesirable Relationship Patterns; (9) Learning to have agency in Relationships; and (10) Flexibility in Relationships and Transitioning to Trauma-Focused Therapy.